Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

DaxibotulinumtoxinA

Aliases
DaxibotulinumtoxinA for injection, Daxxify
Name
DAXXIFY
INN Name
botulinum toxin type A
FDA Approved
Yes

8 clinical trials

1 organization

12 indications

1 document

Indication
Migraine Disorders
Indication
Crow's feet
Indication
Glabellar Lines
Indication
Wrinkles
Indication
Lateral Canthal Lines
Indication
Cervical Dystonia
Indication
Adductor Spasmodic Dysphonia
Indication
Voice Disorders
Indication
Dysphonia
Indication
Aging
Indication
Benign essential blepharospasm
Indication
Hemifacial Spasm
Clinical trial
A Multi-Center Unblinded Proof-of-Concept Study of DaxibotulinumtoxinA for Migraine: the 'EEG Paradigm'
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
Status: Completed, Estimated PCD: 2020-04-23
Clinical trial
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the Combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)
Status: Completed, Estimated PCD: 2020-11-02
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
Status: Completed, Estimated PCD: 2019-12-03
Clinical trial
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections
Status: Completed, Estimated PCD: 2020-03-09
Clinical trial
DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Use of DaxibotulinimtoxinA Injection for Platysma Bands of the Neck
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
The Safety and Efficacy of DaxibotulinumtoxinA-Lanm for Benign Essential Blepharospasm and Hemifacial Spasm
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Document
DailyMed Label: DAXXIFY
Organization
Revance Therapeutics, Inc.